Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.
Paul Edison, MBBS, PhD, FRCPI
Advertisement
Articles by Paul Edison, MBBS, PhD, FRCPI
Advertisement
Latest Updated Articles
AAN 2025: GLP-1 Analogues' Promise in Alzheimer Disease TreatmentPublished: April 7th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Is Berberine Nature’s GLP-1?
2
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
3
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
4
Incidence of Invasive Fungal Infections Following BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
5
